Roche moved to tighten its oncology diagnostics playbook with two pending acquisitions and a sequencing platform launch schedule outlined at its Diagnostics Day. The company said it will acquire PathAI for $1.05 billion to strengthen companion diagnostic development and integrate tools with its Ventana pathology business. Roche also announced a $595 million acquisition of Saga Diagnostics to expand measurable monitoring via Foundation Medicine’s Pathlight MRD technology, including evidence in early-stage breast cancer. Roche added that its new sequencing instrument, Axelios, is expected to be deployed for molecular testing growth across early access sites in the U.S. and Europe.